SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BioLase Technology, Inc. (BLTI)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Trace who wrote (467)11/18/1998 12:16:00 PM
From: J Stone  Read Replies (1) of 706
 
Here's the BW story:

Wednesday, November 18, 1998 08:29 AM

SAN CLEMENTE, Calif.--(BW HealthWire)--Nov. 18, 1998--BIOLASE Technology, Inc. (Nasdaq:BLTI),
a provider of laser-based advanced cosmetic, aesthetic, dental and surgical products, announced today
that Jeffrey W. Jones had been elected president and chief executive officer of BIOLASE effective Nov.
27, 1998.

Jones will succeed Donald A. La Point, who will remain with the company as executive vice president
with principal responsibility for international business development. Jones was also elected a director of
BIOLASE.

Jones has been president and chief executive officer of HGM Medical Lasers, which is based in Salt
Lake City. Jones has been affiliated with HGM Medical Lasers since 1986 and previously served that
company as its director of Marketing and Sales, director-Corporate Development and General Manager.

Privately owned, HGM Medical Lasers is a manufacturer of medical lasers utilized in ophthalmologic,
dental and aesthetic applications. Prior to his twelve years in the medical laser industry, Jones was a
certified public accountant and consultant with Ernst & Whinney. Jones graduated with high honors
from the University of Utah.

Commenting on the election of Jones, Federico Pignatelli, chairman of the BIOLASE Board of
Directors, said, "Jeff Jones is a strong, intelligent and experienced industry executive who is ideally
equipped to lead BIOLASE into the next phase of its development.

"He brings to BIOLASE broad-based knowledge of the medical laser business, including the dental and
cosmetic surgery segments, which should be invaluable as BIOLASE moves to commercialize its
unique technologies that have been the subjects of recent FDA clearances. The new BIOLASE
management team, headed by Jeff Jones and Don La Point, who is remaining with BIOLASE as
Executive Vice President, will, I am convinced, forge BIOLASE into a leading competitor in the
worldwide medical laser market."

Addressing the opportunities and challenges presented at BIOLASE, Jones stated, "BIOLASE
presents a remarkable opportunity, and I am eager for the chance to lead this company.

"In both the aesthetic and dental markets, BIOLASE has advanced proprietary technologies that have
been translated into clinically and technologically superior products that are just now becoming
commercially available. Through these technologies and products, BIOLASE can be propelled into a
leadership position in the medical laser industry."

BIOLASE Technology, Inc., based in San Clemente, manufactures and markets advanced cosmetic,
aesthetic, dental and surgical products, including laser systems and HydroKinetic(TM) surgical cutting
systems, and develops specialized biomaterials for dentistry and other medical specialties.

Last month, BIOLASE received FDA clearance for market Millennium(TM), a HydroKinetic(TM) system
utilizing laser-energized, atomized water droplets as high-speed cutting particles, for dental hard tissue
applications; Millennium(TM) had previously received clearance for soft tissue applications.

In mid-August, the company launched a home product, the LazerSmile(TM) Toothbrush, an optical
toothbrush that uses a light source to enhance whitening agents in a special toothgel compound
developed by BIOLASE.

In July of this year, the company received FDA clearance to market SkinLaser, which is based on the
technology acquired from Laser SkinToner, Inc. earlier in 1998. SkinLaser is the first non-invasive skin
rejuvenation laser designed to reduce wrinkles and is being clinically test for removal of stretch marks.

In July 1997, BIOLASE received clearance from the FDA to market DermaLase(TM), a laser-based
HydroKinetic(TM) surgical tissue cutting system for a broad range of dermatological and general
surgical soft tissue applications.

CONTACT: BIOLASE Technology, Inc.
Stephen R. Tartamella, 949/361-1200 ext. 111

Quote for referenced ticker symbols: BLTI
© 1998, Business Wire
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext